Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 54.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 224,410 shares of the medical research company's stock after selling 265,755 shares during the quarter. Handelsbanken Fonder AB's holdings in Edwards Lifesciences were worth $16,265,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC bought a new stake in Edwards Lifesciences during the 4th quarter valued at $266,000. Empowered Funds LLC grew its stake in shares of Edwards Lifesciences by 6.2% during the fourth quarter. Empowered Funds LLC now owns 25,533 shares of the medical research company's stock worth $1,890,000 after acquiring an additional 1,501 shares during the last quarter. Focus Financial Network Inc. purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $206,000. Stonebridge Financial Group LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $195,000. Finally, Certuity LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $232,000. Institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on EW. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Evercore ISI cut their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research note on Wednesday, February 12th. Morgan Stanley lifted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. Robert W. Baird lifted their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday, April 24th. Finally, Piper Sandler lifted their price target on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $80.20.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $69.81, for a total transaction of $663,195.00. Following the completion of the sale, the vice president now owns 47,206 shares of the company's stock, valued at $3,295,450.86. This trade represents a 16.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daveen Chopra sold 1,500 shares of the business's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the sale, the vice president now directly owns 33,496 shares in the company, valued at $2,514,879.68. This trade represents a 4.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 42,948 shares of company stock valued at $3,122,845 over the last ninety days. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Trading Up 0.5%

NYSE EW traded up $0.39 on Thursday, reaching $75.86. 2,851,331 shares of the company were exchanged, compared to its average volume of 5,223,047. The business's fifty day moving average price is $74.24 and its 200 day moving average price is $72.86. The stock has a market capitalization of $44.50 billion, a P/E ratio of 10.88, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the previous year, the company posted $0.66 earnings per share. The firm's revenue for the quarter was up 6.2% compared to the same quarter last year. Analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.